![Nadim Ahmed](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nadim Ahmed
Chief Executive Officer at
CULLINAN THERAPEUTICS, INC.
Net worth: 2 M $ as of 2026-05-30
Profile
Nadim Ahmed is currently President, Chief Executive Officer & Director at Cullinan Mica Corp., Cullinan Pearl Corp., and Cullinan Therapeutics, Inc. He is also a Director at Family Promise and will be a Director at Disc Medicine, Inc. starting in 2025.
Formerly, Mr. Ahmed was President, Chief Executive Officer & Director at Cullinan Oncology LLC.
From 2019 to 2021, served as President-Hematology at Bristol Myers Squibb Co. From 2010 to 2019, was President-Global Hematology & Oncology at Celgene Corp.
From 1998 to 2010, worked as Senior Marketing Director-Hematologic Oncology at GlaxoSmithKline LLC.
Education includes undergraduate studies at University College London and graduate studies at Loughborough University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-31 | 135,921 ( 0.23% ) | 2 M $ | 2026-05-30 |
Nadim Ahmed active positions
| Companies | Position | Start |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Chief Executive Officer | 2021-10-17 |
| DISC MEDICINE, INC. | Director/Board Member | 2025-07-13 |
Family Promise
 Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Director/Board Member | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Chief Executive Officer | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Chief Executive Officer | - |
Former positions of Nadim Ahmed
| Companies | Position | End |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2020-12-31 |
| CELGENE | Corporate Officer/Principal | 2019-10-31 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 2010-02-28 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Chief Executive Officer | - |
Training of Nadim Ahmed
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
61
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
 Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
 Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
- Stock Market
- Insiders
- Nadim Ahmed
